ArticleJHEP reports : innovation in hepatology2025
Tumor necrosis facilitates perihilar cholangiocarcinoma metastasis by ANGPTL6-augmented vessel permeability and tumor dissemination.
Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The allosteric IDH1 inhibitor ivosidenib overcomes chemoresistance in intrahepatic cholangiocarcinoma models expressing wild-type IDH1.The Journal of clinical investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Tumor necrosis is a pathological feature of solid tumors that is associated with poor prognosis and aggressive characteristics. However, its prognostic significance and underlying mechanisms in perihilar cholangiocarcinoma (pCCA) remain unclear. This study aimed to investigate the prognostic impact, clinic-pathological relevance, molecular regulation, and microenvironment alterations associated with tumor necrosis in pCCA. Methods: We recruited 306 eligible patients with pCCA to assess the prognostic impact and clinic-pathological relevance of pathological tumor necrosis. Laser capture microdissection coupled with high-resolution mass spectrometry was used to identify the molecular changes in pCCA cells within peri-necrotic regions. Single-cell RNA sequencing was performed to elucidate the microenvironment alterations associated with tumor necrosis. Results: Tumor necrosis was present in 52.9% (162/306) of patients with pCCA and was identified as an independent risk factor associated with adverse prognosis (hazard ratio 1.42, 95% CI 1.02-1.97, Conclusions: Pathological tumor necrosis leads to augmented vessel permeability and tumor dissemination in pCCA. ANGPTL6 is a potential target for mitigating the metastatic burden in pCCA. Impact and implications: Pathological tumor necrosis has been identified as an independent risk factor in perihilar cholangiocarcinoma (pCCA), showing positive correlation with metastatic burden. Spatial proteomics and
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.